Navigation Links
New therapeutic target for most common solid cancer in childhood?
Date:2/15/2010

A team of researchers, led by Patrick Mehlen, at Universit de Lyon, France, has identified the protein NT-3 and the cell-surface molecule to which it binds (TrkC) as potential therapeutic targets for the treatment of neuroblastoma the most frequent solid tumor in young children by studying human neuroblastoma cells in vitro and after xenotransplantation into mice and chicks.

In the study, NT-3 was found to be expressed at increased levels in aggressive human neuroblastomas and to block the ability of TrkC to induce tumor cell death by a process known as apoptosis. In vitro analysis of human neuroblastoma cell lines indicated that both decreasing NT-3 expression and culturing in the presence of an antibody that blocked NT-3 binding to TrkC triggered the cells to undergo apoptosis. More importantly, blocking the NT-3/TrkC interaction inhibited tumor growth and metastasis in both a chick and a mouse xenograft model of neuroblastoma. The authors therefore suggest that disrupting the NT-3/TrkC interaction might provide a new approach to treating neuroblastoma, a form of cancer for which treatment options are currently limited.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Northwest Biotherapeutics Inc. Appoints Market Media Connect as Communications Agency of Record
2. Echo Therapeutics Provides Business Update
3. SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea
4. Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
5. Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
6. Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
7. Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions
8. Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada
9. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
10. Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
11. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: